10月9日，拓新药业跌1.02%，成交额7372.32万元。两融数据显示，当日拓新药业获融资买入额820.85 万元，融资偿还1194.87万元，融资净买入-374.02万元。截至10月9日，拓新药业融资融券余额合计1.55 亿元。 融资方面，拓新药业当日融资买入820.85万元。当前融资余额1.55亿元，占流通市值的3.93%，融资余 额超过近一年70%分位水平，处于较高位。 资料显示，拓新药业集团股份有限公司位于河南省新乡市高新区科隆大道515号，成立日期2005年2月3 日，上市日期2021年10月27日，公司主营业务涉及化学合成、生物发酵核苷(酸)类原料药及医药中间体 的研发、生产及销售。主营业务收入构成为：医药中间体62.74%，原料药37.03%，其他(补充)0.23%。 截至9月19日，拓新药业股东户数1.65万，较上期减少26.77%；人均流通股5527股，较上期增加 36.55%。2025年1月-6月，拓新药业实现营业收入1.82亿元，同比减少16.85%；归母净利润-1828.05万 元，同比减少927.39%。 分红方面，拓新药业A股上市后累计派现9463.61万元。近三年，累计派现82 ...

证券日报网讯拓新药业（301089）9月26日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东户数16458户。 ...

Group 1 - On September 25, Toxin Pharmaceutical experienced a decline of 1.54% with a trading volume of 60.37 million yuan [1] - The financing data on the same day showed a financing purchase amount of 3.99 million yuan and a financing repayment of 7.89 million yuan, resulting in a net financing outflow of 3.89 million yuan [1] - As of September 25, the total balance of margin trading for Toxin Pharmaceutical was 157 million yuan, with a financing balance of 156 million yuan, accounting for 4.02% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of July 31, the number of shareholders for Toxin Pharmaceutical increased by 7.72% to 22,500, while the average circulating shares per person decreased by 7.16% to 4,048 shares [2] - For the first half of 2025, Toxin Pharmaceutical reported an operating income of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to the parent company of -18.28 million yuan, a significant year-on-year decrease of 927.39% [2] - Since its A-share listing, Toxin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]

| | 2024年 | 2023 年 | 本年比上年增减 | 2022年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 421,694,066.41 | 835,509,951.28 | -49.53% | 784,722,063.54 | | 归属于上市公司股东 的净利润(元) | -19.884.868.92 | 243,072,734.38 | -108.18% | 286,535.459.93 | | 归属于上市公司股东 的扣除非经常性损益 | -27.255.389.72 | 231.970.162.40 | -111.75% | 276,386,843.54 | | 的净利润(元) | | | | | | 经营活动产生的现金 | 102,668,700.92 | 26,953,364.01 | 280.91% | 268,850,224.01 | | 流量净额(元) | | | | | 中国经济网北京9月25日讯 拓新药业(301089.SZ)2025年半年报显示，报告期内，公司实现营业收入1.82亿元，同 比减少16.85%；归属于上市公司股东的净利 ...

Core Viewpoint - The company has established a subsidiary, Tuoxin Pharmaceutical (Sanya) Co., Ltd., in Hainan Free Trade Port, focusing on the research, production, and sales of pharmaceuticals, health products, and bioactive substances [1] Group 1 - The subsidiary is primarily engaged in the research and development of related products [1] - The company has already commenced some related business activities [1]

Group 1 - The company announced the convening of its sixth employee congress on September 16, 2025 [1] - During the meeting, employees unanimously agreed to elect Mr. Zhang Yongzheng as the employee representative director of the fifth board of directors [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、关于董事辞任的情况 拓新药业集团股份有限公司（以下简称"公司"）收到董事、副总裁王秀强 先生的书面辞职报告，因公司内部工作调整，王秀强先生申请辞去公司第五届董 事会董事职务，辞任后将继续担任公司副总裁职务。王秀强先生的辞任不会导致 公司董事会成员低于法定最低人数，其辞职报告自送达公司董事会之日起生效。 二、关于选举职工代表董事的情况 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2号——创业板上市公司规范运作》等法律法规、规范性文件以及《公司章程》 的有关规定，公司于2025年9月16日召开第六届职工大会第六次会议。经审议， 与会职工一致同意选举张永增先生为公司第五届董事会职工代表董事，任期自本 次职工大会审议通过之日起至第五届董事会任期届满之日止。张永增先生简历详 见附件。 证券代码：301089 证券简称：拓新药业 公告编号：2025-048 拓新药业集团股份有限公司 关于董事辞任暨选举职工代表董事的公告 张永增先生当选公司职工代表董事后，公司第五届董事会中兼任公司高级管 理人员以 ...

Core Viewpoint - The company,拓新药业, has received a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS) for its subsidiary, 河南省核苷药物研究院有限公司, which signifies national and international recognition of its management and technical capabilities [1] Group 1 - The accreditation enhances the company's ability to conduct testing according to national standards, which is crucial for ensuring product quality [1] - This recognition is expected to strengthen the company's product development capabilities and increase customer trust and recognition [1] - The overall impact of this accreditation is anticipated to improve the company's competitive edge and promote sustainable high-quality development [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Henan Nucleoside Pharmaceutical Research Institute Co., Ltd., has received a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS) [1] Group 1 - The accredited institution is Henan Nucleoside Pharmaceutical Research Institute Co., Ltd. [1] - The registration number for the testing and inspection center is CNAS L23965 [1] - The accreditation is effective from September 1, 2025, and will expire on August 31, 2031 [1]

证券代码：301089 证券简称：拓新药业 公告编号：2025-047 生效日期：2025年9月01日 截止日期：2031年8月31日 证书主要内容：河南省核苷药物研究院有限公司符合ISO/IEC 17025：2017 《检测和校准实验室能力的通用要求》（CNAS-CL01《检测和校准实验室能力认 可准则》）的要求，具备承担本证书附件所列服务能力，予以认可。 拓新药业集团股份有限公司 关于全资子公司获得中国合格评定国家认可委员会（CNAS） 实验室认可证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）全资子公司河南省核苷药 物研究院有限公司（以下简称"药物研究院"）于近日收到中国合格评定国家认 可委员会（英文名称为"China National Accreditation Service for Conformity Assessment"，以下简称"CNAS"）授予的实验室认可证书，现将相关事宜公告 如下： 一、证书内容 获得机构名称：河南省核苷药物研究院有限公司 检验检测中心注册号：CNAS L239 ...